Cargando…

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries

OBJECTIVES: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical practice and to anchor these results with a general...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delcoigne, Benedicte, Ljung, Lotta, Provan, Sella A, Glintborg, Bente, Hetland, Merete Lund, Grøn, Kathrine Lederballe, Peltomaa, Ritva, Relas, Heikki, Turesson, Carl, Gudbjornsson, Bjorn, Michelsen, Brigitte, Askling, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120408/ https://www.ncbi.nlm.nih.gov/pubmed/35318218 http://dx.doi.org/10.1136/annrheumdis-2021-221996

Ejemplares similares

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

Siblings of patients with rheumatoid arthritis have an increased mortality rate: a Swedish cohort study
por: Westerlind, Helga, et al.
Publicado: (2020)

Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
por: Cordtz, Rene Lindholm, et al.
Publicado: (2022)

Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?
por: Waldenlind, Kristin, et al.
Publicado: (2020)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study
por: Tidblad, Liselotte, et al.
Publicado: (2022)

Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
por: Bower, Hannah, et al.
Publicado: (2023)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
por: Molander, Viktor, et al.
Publicado: (2023)

Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation
por: Ljung, Lotta, et al.
Publicado: (2018)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
por: Frisell, Thomas, et al.
Publicado: (2023)

Is rheumatoid arthritis a risk factor for acute coronary syndrome also among individuals at elevated risk, such as individuals presenting with acute chest pain?
por: Svensson, Per, et al.
Publicado: (2020)

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis
por: Sharma, Chanakya, et al.
Publicado: (2020)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
por: Saleem, Benazir, et al.
Publicado: (2022)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment
por: Novella -Navarro, Marta, et al.
Publicado: (2023)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial
por: Hebing, Renske CF, et al.
Publicado: (2022)

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
por: Yuan, Haoming, et al.
Publicado: (2023)

Cost-effectiveness of motivational counselling and text reminders in patients with rheumatoid arthritis: results based on a randomised clinical trial
por: Sørensen, Jan, et al.
Publicado: (2022)

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
por: Lindström, Ulf, et al.
Publicado: (2021)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
por: Redeker, Imke, et al.
Publicado: (2022)

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
por: van Vollenhoven, Ronald, et al.
Publicado: (2019)

How do multiple long-term conditions impact on the cost-of-illness in early rheumatoid arthritis?
por: Hsieh, Ping-Hsuan, et al.
Publicado: (2022)

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis
por: Baradat, Claire, et al.
Publicado: (2017)

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ffq5p3k7pkq82982hknm739ope